首页 > immunodx > immunodx/Recombinant HIV-1 IIIB Glycoprotein gp120 (CHO)/Lyophilized - 100 ug/1041L

提醒：代购产品，无质量问题不接受退换货，下单前请仔细核对信息。下单后请及时联系客服核对商品价格，订单生效后再付款。

immunodx/Recombinant HIV-1 IIIB Glycoprotein gp120 (CHO)/Lyophilized - 100 ug/1041L

价格：

登录查看

自营商城

解放采购

正品保障

及时交付

厂家直采

一站服务

货号：

1041L

品牌：

immunodx

会员服务：

尊享会员价

贵宾专线

运费优惠

闪电退款

福利优惠

上门换新

友情提示

以上价格仅为参考，请联系客服询价。

免费咨询热线

4000-520-616

产品说明

Product Specifications: Item# 1041: Recombinant HIV-1 IIIB Glycoprotein gp120 (CHO) Concentration: See vial Diluent: PBS Purity: >95% Stabilizer: None Preservative: NoneStorage: -75°C Physical State: Frozen Liquid Stability: At least 6 months at -75°C.Applications: In-Vitro Diagnostics, CD4 Binding, T-Cell Activation.Description: Full length Recombinant HIV-1 IIIB gp120 glycoprotein produced in the CHO Expression System.Purification: This protein is purified by immunoaffinity chromatography to >95% purity as determined by SDS-PAGE, reduced. Specificity: This protein binds to murine monoclonal antibodies of defined epitope specificity and human serum polyclonal antibodies in ELISA and Western ELISA. Biological Activity: This protein binds to human T-cell receptor CD4 in ELISA and Western ELISA as determined by CD4/gp120/Anti-gp120 mAb-peroxidase capture ELISA. This protein activates human T-Lymphocytes (CD4+, CD4-), in vitro, as measured by RNA synthesis during G0 to G1 transition phase of antigen-binding competent cells. Application and Instructions for useRecommended concentrations for use are approximate values. A dose dependent response assay should be performed to determine the optimal concentration for use in specific applications. ELISA and Western ELISA require 10-100ng protein depending on the nature and affinity of the detection reagent. Human serum polyclonal antibodies yield titers of 1:1000 or greater at 100ng of solid phase protein under standard ELISA conditions.Item#: 1041-P Peroxidase-Conjugated rgp120 HIV-1 IIIB Application: Human diagnostics, CD4 binding, Drug screening, Human T-cell CD4 studies. Safety Study of rgp120/HIV-1IIIB VaccineRecent evidence suggests that gp120 is the HIV-1 protein with the greatest potential as a vaccine against HIV-1 infection. The gp120 envelope protein may be produced by recombinant DNA technology, and studies have shown that the vaccine is capable of eliciting neutralizing antibody activity in both rodents and nonhuman primate species.Official Study Title: A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)Disease: HIV InfectionsTreatment: Biological: rgp120/HIV-1IIIB and Biological: rgp120/HIV-1MN ORIGINAL DESIGN: Twenty-eight subjects will be randomized to receive 100 or 300 mcg rgp120/HIV-1IIIB vaccine (gp120 vaccine) or matching placebo. For each dose level, 10 subjects will receive vaccine and four subjects will receive matching placebo. Injections are given intramuscularly at 0, 4, and 32 weeks. Each subject receiving treatment at the lower dose level must be monitored for unacceptable toxicity for at least 2 weeks following the initial immunization before his or her second dose is administered and before treatment at the higher dose level begins. Subjects are followed for at least 12 months.AMENDED 11/17/93: Selected subjects from VEU 006 or VEU 006 Rollover study will receive two injections of MN rgp120 vaccine, administered 28 days apart beginning 10-16 months after their last injection. Eight additional clinic visits will be required. Subjects are followed for at least 6 months.CHO- expressed HIV-1IIIB rgp120 (2.5 μg) and biotinylated cyclic V2-TH023 peptide (1 μg and 5 μg) were incubated with RPMI8866 cells

ImmunoDX，LLC（IDX）-前身为ImmunoDiagnostics-为人类T细胞研究/诊断，艾滋病，HCV，HBV，TB，癌症和关节炎的诊断和治疗开发开发，制造和销售各种特种生物学。我们的独家产品系列-重组蛋白，单克隆/多克隆抗体和其他衍生试剂（FITC，过氧化物酶，生物素，顺磁性结合物）的生产符合纯度，特异性和生物活性的最高质量标准。